55.12
price down icon0.95%   -0.53
pre-market  プレマーケット:  55.50   0.38   +0.69%
loading
前日終値:
$55.65
開ける:
$55.65
24時間の取引高:
1.45M
Relative Volume:
0.71
時価総額:
$10.65B
収益:
$3.29B
当期純損益:
$268.74M
株価収益率:
40.22
EPS:
1.3704
ネットキャッシュフロー:
$759.12M
1週間 パフォーマンス:
-4.82%
1か月 パフォーマンス:
+6.39%
6か月 パフォーマンス:
+6.47%
1年 パフォーマンス:
-1.99%
1日の値動き範囲:
Value
$54.61
$55.83
1週間の範囲:
Value
$54.61
$58.26
52週間の値動き範囲:
Value
$49.26
$66.28

Biomarin Pharmaceutical Inc Stock (BMRN) Company Profile

Name
名前
Biomarin Pharmaceutical Inc
Name
セクター
Healthcare (1107)
Name
電話
(415) 506-6700
Name
住所
105 DIGITAL DRIVE, NOVATO, CA
Name
職員
3,221
Name
Twitter
Name
次回の収益日
2026-08-03
Name
最新のSEC提出書
Name
BMRN's Discussions on Twitter

Compare BMRN vs VRTX, REGN, ARGX, ALNY, RVMD

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
BMRN icon
BMRN
Biomarin Pharmaceutical Inc
55.12 10.76B 3.29B 268.74M 759.12M 1.3704
VRTX icon
VRTX
Vertex Pharmaceuticals Inc
453.17 114.33B 12.34B 4.34B 3.71B 16.87
REGN icon
REGN
Regeneron Pharmaceuticals Inc
614.73 64.47B 14.92B 4.42B 3.79B 41.04
ARGX icon
ARGX
Argen X Se Adr
878.49 54.99B 4.16B 1.29B 734.26M 19.58
ALNY icon
ALNY
Alnylam Pharmaceuticals Inc
281.90 38.42B 4.29B 577.22M 641.34M 4.2086
RVMD icon
RVMD
Revolution Medicines Inc
156.58 34.03B 742.00K -1.37B -1.07B -7.0731

Biomarin Pharmaceutical Inc Stock (BMRN) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2026-04-27 再開されました Morgan Stanley Overweight
2026-01-28 再開されました Barclays Overweight
2026-01-20 アップグレード Canaccord Genuity Hold → Buy
2025-12-03 ダウングレード Leerink Partners Outperform → Market Perform
2025-11-06 ダウングレード Stifel Buy → Hold
2025-09-08 開始されました H.C. Wainwright Neutral
2025-09-03 開始されました Raymond James Outperform
2025-07-03 再開されました Morgan Stanley Overweight
2025-02-24 アップグレード Oppenheimer Perform → Outperform
2024-11-15 開始されました Wolfe Research Outperform
2024-10-30 ダウングレード William Blair Outperform → Mkt Perform
2024-10-10 再開されました Raymond James Outperform
2024-08-20 アップグレード Bernstein Mkt Perform → Outperform
2024-05-17 ダウングレード Robert W. Baird Outperform → Neutral
2024-05-14 開始されました Evercore ISI Outperform
2023-11-15 開始されました Wells Fargo Overweight
2023-10-23 アップグレード Bernstein Underperform → Mkt Perform
2023-09-28 開始されました Raymond James Mkt Perform
2023-09-18 開始されました UBS Buy
2023-07-27 開始されました Scotiabank Sector Perform
2023-07-05 アップグレード BMO Capital Markets Market Perform → Outperform
2023-06-14 再開されました Credit Suisse Outperform
2023-03-21 開始されました Bernstein Underperform
2023-02-22 ダウングレード Oppenheimer Outperform → Perform
2023-02-21 開始されました Citigroup Neutral
2023-01-30 開始されました BMO Capital Markets Market Perform
2023-01-18 開始されました Canaccord Genuity Hold
2022-10-31 アップグレード Oppenheimer Perform → Outperform
2022-07-13 開始されました Cantor Fitzgerald Overweight
2022-06-13 再開されました Wedbush Neutral
2022-04-25 アップグレード Morgan Stanley Equal-Weight → Overweight
2021-11-22 アップグレード William Blair Mkt Perform → Outperform
2021-10-07 再開されました Jefferies Buy
2021-09-09 アップグレード Stifel Hold → Buy
2021-06-04 再開されました Robert W. Baird Outperform
2021-04-26 再開されました Credit Suisse Outperform
2021-03-04 再開されました Guggenheim Buy
2021-03-01 アップグレード Evercore ISI In-line → Outperform
2020-08-20 ダウングレード Citigroup Buy → Neutral
2020-08-20 ダウングレード William Blair Outperform → Mkt Perform
2020-08-19 ダウングレード Evercore ISI Outperform → In-line
2020-08-19 ダウングレード RBC Capital Mkts Outperform → Sector Perform
2020-08-19 ダウングレード Stifel Buy → Hold
2020-07-08 ダウングレード Morgan Stanley Overweight → Equal-Weight
2020-07-06 繰り返されました Citigroup Buy
2020-01-28 開始されました BMO Capital Markets Market Perform
2020-01-27 開始されました BMO Capital Markets Market Perform
2020-01-24 アップグレード RBC Capital Mkts Sector Perform → Outperform
2019-11-27 アップグレード Barclays Equal Weight → Overweight
2019-11-12 開始されました SunTrust Buy
2019-10-17 再開されました BofA/Merrill Buy
2019-05-23 再開されました Citigroup Buy
2019-04-09 再開されました Raymond James Outperform
2019-01-02 ダウングレード Raymond James Outperform → Mkt Perform
2018-12-14 開始されました Wolfe Research Outperform
2018-10-01 開始されました Cantor Fitzgerald Overweight
2018-08-07 繰り返されました Stifel Buy
2018-08-03 繰り返されました Stifel Buy
すべてを表示

Biomarin Pharmaceutical Inc (BMRN) 最新ニュース

pulisher
Jun 15, 2026

Daily Brief United States: SpaceX, Crude Oil, DPC Holdings, CRB Commodity Index, Vistra , AnaptysBio Inc, Kardigan, Aes Corp, GE Vernova , Biomarin Pharmaceutical and more - Smartkarma

Jun 15, 2026
pulisher
Jun 13, 2026

(BMRN) and the Role of Price-Sensitive Allocations - Stock Traders Daily

Jun 13, 2026
pulisher
Jun 13, 2026

BioMarin shares drop 4% as Voxzogo trials are discontinued - MSN

Jun 13, 2026
pulisher
Jun 12, 2026

Janus Henderson High-Yield Fund's BioMarin Pharmaceutical Inc(BMRN) Holding History - GuruFocus

Jun 12, 2026
pulisher
Jun 12, 2026

BMRN News | BIOMARIN PHARMACEUTICAL INC (NASDAQ:BMRN) - ChartMill

Jun 12, 2026
pulisher
Jun 12, 2026

Layoff Tracker: Genentech R&D cuts include longtime top exec - BioSpace

Jun 12, 2026
pulisher
Jun 10, 2026

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN): A Decent Value Play with Strong Fundamentals - ChartMill

Jun 10, 2026
pulisher
Jun 09, 2026

BioMarin Pharmaceutical (BMRN) Gains 2.58% as Stock Approaches Key Resistance LevelDiagonal Spread Trade - newsline.com

Jun 09, 2026
pulisher
Jun 09, 2026

BMRN Technical Analysis & Stock Price Forecast - Intellectia AI

Jun 09, 2026
pulisher
Jun 08, 2026

BioMarin Pharmaceutical's Revenue Guidance Boost Reflects Pipeline Progress and Acquisition GrowthEarnings Cycle Report - newsline.com

Jun 08, 2026
pulisher
Jun 08, 2026

Biomarin Pharmaceutical (BMRN): Most Undervalued Stocks to Buy and Hold for 2 Years - Yahoo Finance

Jun 08, 2026
pulisher
Jun 08, 2026

BioMarin Pharmaceutical Inc. (BMRN) Stock Analysis: Exploring A 54.74% Potential Upside - DirectorsTalk Interviews

Jun 08, 2026
pulisher
Jun 07, 2026

BioMarin (BMRN) up 0.2% since last earnings report: Can it continue? - MSN

Jun 07, 2026
pulisher
Jun 06, 2026

10 Most Undervalued Stocks to Buy and Hold for 2 Years - Insider Monkey

Jun 06, 2026
pulisher
Jun 05, 2026

BMRN stock down on mixed results from rare disease therapy study - MSN

Jun 05, 2026
pulisher
Jun 05, 2026

BioMarin's Voxzogo meets goal in late-stage study for hypochondroplasia - MSN

Jun 05, 2026
pulisher
Jun 05, 2026

How BioMarin Pharma is Planning to Grow Their Revenue? - The American Reporter

Jun 05, 2026
pulisher
Jun 05, 2026

BioMarin’s VOXZOGO Win In Hypochondroplasia Shapes Rare Disease Growth Story - Yahoo Finance

Jun 05, 2026
pulisher
Jun 05, 2026

BioMarin Pharmaceutical Inc. 2026 8-K Filing Summary: Company Information, Stock Details, and SEC Compliance - Minichart

Jun 05, 2026
pulisher
Jun 04, 2026

BioMarin (BMRN) director Athena Countouriotis receives 7,490-share RSU grant - Stock Titan

Jun 04, 2026
pulisher
Jun 04, 2026

BioMarin (NASDAQ: BMRN) director receives 7,490-share RSU grant - Stock Titan

Jun 04, 2026
pulisher
Jun 04, 2026

BioMarin (BMRN) director Maykin Ho receives 7,490 stock units - Stock Titan

Jun 04, 2026
pulisher
Jun 04, 2026

Director at BioMarin (NASDAQ: BMRN) awarded 7,490 RSUs - Stock Titan

Jun 04, 2026
pulisher
Jun 04, 2026

BioMarin (BMRN) director Mark Enyedy receives 7,490-share RSU grant - Stock Titan

Jun 04, 2026
pulisher
Jun 04, 2026

BioMarin (BMRN) director Willard H. Dere receives 7,490-share RSU grant - Stock Titan

Jun 04, 2026
pulisher
Jun 04, 2026

BioMarin (BMRN) director Ian T. Clark awarded 7,490 restricted stock units - Stock Titan

Jun 04, 2026
pulisher
Jun 04, 2026

BioMarin (BMRN) director gets 7,490 RSUs, holds 21,045 shares - Stock Titan

Jun 04, 2026
pulisher
Jun 04, 2026

BioMarin (BMRN) director receives 7,490 RSUs in stock grant - Stock Titan

Jun 04, 2026
pulisher
Jun 04, 2026

BioMarin Shareholders Approve 2026 Governance and Equity Plan - TipRanks

Jun 04, 2026
pulisher
Jun 04, 2026

Shareholders of BioMarin (NASDAQ: BMRN) back equity plan and board slate - Stock Titan

Jun 04, 2026
pulisher
Jun 04, 2026

Ionis, Alnylam, BioMarin up as Citi starts at buy on catalyst and growth outlook - MSN

Jun 04, 2026
pulisher
Jun 04, 2026

A Look At BioMarin Pharmaceutical (BMRN) Valuation After Recent Share Price Strength - Sahm

Jun 04, 2026
pulisher
Jun 04, 2026

BioMarin gains on Voxzogo phase 3 results - MSN

Jun 04, 2026
pulisher
Jun 03, 2026

BioMarin (BMRN) Up 0.2% Since Last Earnings Report: Can It Continue? - Yahoo Finance

Jun 03, 2026
pulisher
Jun 03, 2026

BioMarin Pharmaceutical Hits Day High with 8.63% Surge in Stock Price - Markets Mojo

Jun 03, 2026
pulisher
Jun 02, 2026

Responsive Playbooks and the BMRN Inflection - Stock Traders Daily

Jun 02, 2026
pulisher
Jun 01, 2026

BioMarin Pharmaceutical Inc. (BMRN): Analyst Consensus Suggests a 53% Upside for a Biotech Innovator - DirectorsTalk Interviews

Jun 01, 2026
pulisher
Jun 01, 2026

BMRN Q1 2026 Earnings: EPS Misses Estimates but Stock Surges 8.63%Earnings Power Value - newsline.com

Jun 01, 2026
pulisher
May 30, 2026

BioMarin Pharmaceutical Inc. (BMRN) A Stock that Could 10x by 2030 on Pipeline Development - Insider Monkey

May 30, 2026
pulisher
May 29, 2026

5 Stocks That Could 10X by 2030 - Insider Monkey

May 29, 2026
pulisher
May 29, 2026

Kim Warner Builds Pathways for Early-Career Professionals | BioMarin - BioMarin Pharmaceutical

May 29, 2026
pulisher
May 28, 2026

JPMorgan says large-cap biotech is back as profits and pipelines fuel upside - Investing.com

May 28, 2026
pulisher
May 28, 2026

BioMarin Pharmaceutical (BMRN) Edges Higher as Biotech Sector Shows ResilienceRisk Reward Setups - newsline.com

May 28, 2026
pulisher
May 27, 2026

Earnings call transcript: BioMarin Q1 2026 results beat forecasts, stock dips - Investing.com Nigeria

May 27, 2026
pulisher
May 26, 2026

Duchenne Muscular Dystrophy Clinical Trial Pipeline: DelveInsight Highlights Major Advances, Transformative Therapies, and 75+ Leading Players Wheeling the Therapeutics Landscape - GlobeNewswire Inc.

May 26, 2026
pulisher
May 26, 2026

8 New 5-Star Stocks This Week - Morningstar

May 26, 2026
pulisher
May 26, 2026

A Look At BioMarin Pharmaceutical (BMRN) Valuation After Positive Voxzogo Phase 3 Trial Results - Sahm

May 26, 2026
pulisher
May 25, 2026

BioMarin Pharmaceutical Inc. (BMRN) Stock Analysis: Navigating a Potential 62.41% Upside Amidst Biotech Innovations - DirectorsTalk Interviews

May 25, 2026
pulisher
May 23, 2026

CCORF Maintains Biomarin Pharmaceutical(BMRN.US) With Buy Rating, Cuts Target Price to $111 - Moomoo

May 23, 2026
pulisher
May 23, 2026

Why BioMarin Pharmaceutical (BMRN) Stock Is Trading Up Today - Yahoo Finance

May 23, 2026
pulisher
May 22, 2026

Understanding the Setup: (BMRN) and Scalable Risk - Stock Traders Daily

May 22, 2026

Biomarin Pharmaceutical Inc (BMRN) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading
$30.41
price up icon 1.27%
$55.40
price up icon 6.27%
$89.50
price down icon 1.43%
$54.21
price down icon 0.11%
ONC ONC
$263.92
price down icon 1.60%
$156.58
price down icon 2.17%
大文字化:     |  ボリューム (24 時間):